Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.Atsena has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 16, 2020 | Series A | $55M | 1 | — | — | Detail |
| Apr 1, 2020 | Series A | $8.15M | 1 |
Foundation Fighting Blindness
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Foundation Fighting Blindness
|
Yes | Series A |
Retinal Degeneration Fund
|
— | Series A |